CRC is unusual compared to other cancers in that loss of function mutations in APC are much more frequent than activating mutations in β-catenin (i.e. in exon 3), ∼75% compared to ∼5%, respectively (TCGA, 2012). The gene discussed is APC; the disease is cancer.